Travere Therapeutics Inc at Bank of America Healthcare Conference Transcript
My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. It's my pleasure today to introduce Eric Dube, CEO of Travere Therapeutics.
Eric, would you like to start off with some opening remarks and then we can get into Q&A?
Sure. Well, first of all, thank you for hosting us today. And I would encourage all of you to take a look at our investor deck on our website for forward-looking statements.
What I can say is, we're in a very exciting time of growth for Travere Therapeutics as we look to bring our lead pipeline asset sparsentan to market, as well as to advance an earlier-stage clinical asset. We're a company that's based in San Diego and exclusively focused on rare disease with a particular focus on rare kidney, liver and metabolic disease.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |